newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

- Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 - -